Miramonti
Lifer
- Aug 26, 2000
- 28,651
- 100
- 91
The NY Times had an article on how Purdue Pharma (makers of oxycontin) fueled addictions by [falsely] claiming it was a 12-hour dosing pain reliever, in order to separate itself from it's shorter dosing competitors. Problem was it wasn't a reliable 12-hour dosing drug. That lead to more extreme (painful) lows when people's pain relief stopped between pills, and then when the next dose was taken, more extreme highs resulted.
Trials often showed it wasn't a reliable 12-hour dosing pain relief, but problem was that the trials would either get cancelled when they were failing, or the people who couldn't handle the 12-hour dosing had to quit them.
At the same time, insurance companies would only accept prescriptions at the 12-hour dosing, so many patients who were prescribed it for pain were screwed. Also, Purdue would send their sales hawks to doctors that would prescribe it for more frequent intervals than 12 hours to b!tch slap them, in order to try and preserve the 12-hour distinction from it's competitors.
A year or two after the drug was approved in the mid-90's (1995?), the chairman (?) of the fda, responsible for it's approval, went to work for Purdue.
Purdue was later fined $634 million for deceiving the public about it's addiction risk, a drop in the bucket to the billions they've made on it.
Trials often showed it wasn't a reliable 12-hour dosing pain relief, but problem was that the trials would either get cancelled when they were failing, or the people who couldn't handle the 12-hour dosing had to quit them.
At the same time, insurance companies would only accept prescriptions at the 12-hour dosing, so many patients who were prescribed it for pain were screwed. Also, Purdue would send their sales hawks to doctors that would prescribe it for more frequent intervals than 12 hours to b!tch slap them, in order to try and preserve the 12-hour distinction from it's competitors.
A year or two after the drug was approved in the mid-90's (1995?), the chairman (?) of the fda, responsible for it's approval, went to work for Purdue.
Purdue was later fined $634 million for deceiving the public about it's addiction risk, a drop in the bucket to the billions they've made on it.